Pasar al contenido principal

BÚSQUEDA DE ENFERMEDADES RENALES HEREDITARIAS NO SOSPECHADAS: UNA AGUJA EN UN PAJAR.

PI22/00361

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Artificial intelligence, a new field of knowledge for nephrologists

  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • R. Viera, Elizabeth
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
  • De Maeztu, Gabriel
  • Nicolau, Anna
  • Furlano, Monica|||0000-0003-1025-3901
  • Torra Balcells, Roser|||0000-0001-8714-2332
Artificial intelligence (AI) is a science that involves creating machines that can imitate human intelligence and learn. AI is ubiquitous in our daily lives, from search engines like Google to home assistants like Alexa and, more recently, OpenAI with its chatbot. AI can improve clinical care and research, but its use requires a solid understanding of its fundamentals, the promises and perils of algorithmic fairness, the barriers and solutions to its clinical implementation, and the pathways to developing an AI-competent workforce. The potential of AI in the field of nephrology is vast, particularly in the areas of diagnosis, treatment and prediction. One of the most significant advantages of AI is the ability to improve diagnostic accuracy. Machine learning algorithms can be trained to recognize patterns in patient data, including lab results, imaging and medical history, in order to identify early signs of kidney disease and thereby allow timely diagnoses and prompt initiation of treatment plans that can improve outcomes for patients. In short, AI holds the promise of advancing personalized medicine to new levels. While AI has tremendous potential, there are also significant challenges to its implementation, including data access and quality, data privacy and security, bias, trustworthiness, computing power, AI integration and legal issues. The European Commission's proposed regulatory framework for AI technology will play a significant role in ensuring the safe and ethical implementation of these technologies in the healthcare industry. Training nephrologists in the fundamentals of AI is imperative because traditionally, decision-making pertaining to the diagnosis, prognosis and treatment of renal patients has relied on ingrained practices, whereas AI serves as a powerful tool for swiftly and confidently synthesizing this information. plans, leading to better patient outcomes. However, the implementation of AI in healthcare faces several challenges. The European Commission's proposed regulatory framework aims to promote the safe and ethical use of AI in healthcare. To fully leverage the benefits of AI, nephrologists and other healthcare professionals need to be educated about its fundamentals and its potential applications in routine patient care. This will enable them to effectively utilize AI technologies and provide better care for kidney patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic study in young patients with chronic kidney disease stage G5 from unknown etiology. The GENSEN study design Estudio genético en pacientes jóvenes con enfermedad renal crónica avanzada de etiología no filiada. Diseño del estudio GENSEN

  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Quiroga, Borja|||0000-0001-5730-1929
  • García-Aznar, José M.
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ortiz, Alberto|||0000-0002-9805-9523
  • de Sequera, Patricia|||0000-0001-7705-9228
Introduction: Chronic kidney disease (CKD) of unknown etiology is one of the main causes of renal replacement therapy in our environment. Previous studies in other territories suggest that hereditary diseases could be one of the potential causes of this pathology, especially in younger patients. The GENSEN study will evaluate the presence of pathogenic genetic variants in subjects who have developed CKD category G5 before the age of 46, of unknown etiology. Methods: Observational, prospective and multicenter study, which evaluates the diagnostic usefulness of massive high-throughput sequencing (HTS) directed at a set of genes, in identifying the cause of CKD. Patients from all over Spain will be included, from whom a blood or saliva sample will be extracted, subsequently analyzing a panel of 529 genes associated with hereditary kidney disease. This publication communicates the study protocol and design. Conclusion: The GENSEN study will allow to evaluate the diagnostic performance of a gene panel study in young subjects from our environment with the development of category G5 CKD without a clear cause. An etiological diagnosis would offer potential benefits for patients and relatives (targeted therapies, clinical trials, detection of extrarenal manifestations, evaluation of relatives for living kidney donation, estimation of the risk of recurrence in the kidney graft, genetic counseling, among others) and would allow genetic study to be brought closer to nephrology in our country.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Mild Presentation of X-Linked Hypophosphatemia Caused by a Non-Canonical Splice Site Variant in the PHEX Gene

  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Herreros García, Alba|||0009-0003-0451-7568
  • Pybus, Marc|||0000-0002-6195-5738
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Furlano, Monica|||0000-0003-1025-3901
  • Garcia Borau, Maria José|||0000-0002-8223-8033
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ars, Elisabet|||0000-0002-4118-4358
X-linked hypophosphatemia (XLH) is a rare inherited disorder of renal phosphate wasting with a highly variable phenotype caused by loss-of-function variants in the PHEX gene. The diagnosis of individuals with mild phenotypes can be challenging and often delayed. Here, we describe a three-generation family with a very mild clinical presentation of XLH. The diagnosis was unexpectedly found in a 39-year-old woman who was referred for genetic testing due to an unclear childhood diagnosis of a tubulopathy. Genetic testing performed by next-generation sequencing using a kidney disease gene panel identified a novel non-canonical splice site variant in the PHEX gene. Segregation analysis detected that the consultand's father, who presented with hypophosphatemia and decreased tubular phosphate reabsorption, and the consultand's son also carried this variant. RNA studies demonstrated that the non-canonical splice site variant partially altered the splicing of the PHEX gene, as both wild-type and aberrant splicing transcripts were detected in the two male members with only one copy of the PHEX gene. In conclusion, this case contributes to the understanding of the relationship between splicing variants and the variable expressivity of XLH disease. The mild phenotype of this family can be explained by the coexistence of PHEX transcripts with aberrant and wild-type splicing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Lipska-Ziętkiewicz, Beata S.|||0000-0002-4169-9685
  • Acke, Frederic|||0000-0001-6312-4260
  • Antignac, Corinne|||0000-0002-9934-4940
  • Becker, Jan Ulrich|||0000-0003-2929-8085
  • Cornec-Le Gall, Emilie|||0000-0003-1958-4459
  • van Eerde, Albertien M.|||0000-0001-5953-5956
  • Feltgen, Nicolas|||0000-0002-6857-3003
  • Ferrari, Rossella
  • Gale, Daniel|||0000-0002-9170-1579
  • Gear, Susie
  • Gross, Oliver|||0000-0002-8390-8852
  • Haeberle, Stefanie
  • Heidet, Laurence|||0000-0002-1362-5515
  • Lennon, Rachel|||0000-0001-6400-0227
  • Massella, Laura|||0000-0001-5796-3965
  • Pfau, Kristina|||0000-0002-3642-3502
  • Venegas, María del Prado|||0000-0001-9048-4501
  • Topaloglu, Rezan|||0000-0002-6423-0927
  • Wlodkowski, Tanja
  • Zealey, Heidi
Glomerular nephropathy resulting from the genetic defects in COL4A3/4/5 genes including the classical Alport syndrome is the second most common hereditary kidney disease characterized by persistent haematuria progressing to the need for kidney replacement therapy, frequently associated with sensorineural deafness, and occasionally with ocular anomalies. Diagnosis and management of COL4A3/4/5 glomerulopathy is a great challenge due to its phenotypic heterogeneity, multiple modes of inheritance, variable expressivity, and disease penetrance of individual variants as well as imperfect prognostic and progression factors and scarce and limited clinical trials, especially in children. As a joint initiative of the European Rare Kidney disease reference Network (ERKNet), European Renal Association (ERA Genes&Kidney), and European Society for Paediatric Nephrology (ESPN) Inherited renal disorders working group, a team of experts including adult and paediatric nephrologists, kidney geneticists, audiologists, ophthalmologists, and a kidney pathologist were selected to perform a systematic literature review on 21 clinically relevant PICO (Patient or Population covered, Intervention, Comparator, Outcome) questions. The experts formulated recommendations and formally graded them at a consensus meeting with input from patient representatives and a voting panel of nephrologists representing all regions of the world. Genetic diagnostics comprising joint analysis of COL4A3/4/5 genes is already the key diagnostic test during the initial evaluation of an individual presenting with persistent haematuria, proteinuria, kidney failure of unknown origin, focal segmental sclerosis of unknown origin, and possibly cystic kidney disease. Early renin-angiotensin system blockade is the standard of care therapy; sodium-glucose cotransporter-2 inhibitors may be added in adults with proteinuria and chronic kidney disease. Relatives with heterozygous COL4A3/4/5 variants should only be considered as the last possible resource for living kidney donation. This guideline provides guidance for the diagnosis and management of individuals with pathogenic variants in COL4A3/4/5 genes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

When should the nephrologist think about genetics in patients with glomerular diseases?

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Barros, Xoana|||0000-0001-9690-9769
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • Furlano, Monica|||0000-0003-1025-3901
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Pybus, Marc|||0000-0002-6195-5738
  • Shabaka, Amir|||0000-0001-7039-4701
  • Viera, Elizabeth|||0000-0002-3548-7061
  • Ars, Elisabet|||0000-0002-4118-4358
This review discusses the significance of genetics in diagnosing glomerular diseases. Advances in genetic testing, particularly next-generation sequencing, have improved the accessibility and accuracy of diagnosing monogenic diseases, allowing for targeted gene panels and whole-exome/genome sequencing to identify genetic variants associated with glomerular diseases. Key indicators for considering a genetic cause include the age of onset, extrarenal features, family history, and inconclusive kidney biopsy results. Early-onset diseases, for instance, have a higher likelihood of being genetically caused, while extrarenal manifestations can also suggest an underlying genetic condition. A thorough family history can reveal patterns of inheritance that point to monogenic causes, although complexities like incomplete penetrance, skewed X inactivation and mosaicism can complicate the assessment. Also, autosomal recessive conditions imply asymptomatic parents, making genetic suspicion less likely, while de novo mutations can occur without any family history, further obscuring genetic assessment. Focal segmental glomerulosclerosis (FSGS) is characterized by podocyte injury and depletion, presenting in various forms, including primary, genetic, and secondary FSGS. Accurate classification of FSGS patients based on clinical and histological features is essential for guiding treatment decisions, optimizing therapeutic plans, avoiding unnecessary immunosuppression, and predicting relapse risk after kidney transplantation. Overall, a clinicopathological approach, enriched by genetic testing, offers a precise framework for diagnosis and management in glomerular diseases. Future directions for research and clinical practice include potential advancements in genetic testing and personalized medicine, which could further improve diagnostic precision and individualized treatment strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased prevalence of kidney cysts in individuals carrying heterozygous COL4A3 or COL4A4 pathogenic variants

  • Furlano, Monica|||0000-0003-1025-3901
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Pybus, Marc|||0000-0002-6195-5738
  • Martínez, Víctor
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Rius Peris, Asunción
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Berná, Gerson
  • Mazon, Jaime
  • Hernández Mancera, Jonathan|||0000-0002-2267-7536
  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • Viera, Elizabeth|||0000-0002-3548-7061
  • Gich, Ignasi|||0000-0003-3975-6588
  • Pérez, Hugo Vergara
  • Gomá-Garcés, Elena
  • Albero Dolon, José Luis
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
Clinical variability among individuals with heterozygous pathogenic/likely pathogenic (P/LP) variants in the COL4A3 / COL4A4 genes (also called autosomal dominant Alport syndrome or COL4A3/COL4A4 -related disorder) is huge; many individuals are asymptomatic or show microhematuria, while others may develop proteinuria and chronic kidney disease (CKD). The prevalence of simple kidney cysts (KC) in the general population varies according to age, and patients with advanced CKD are prone to have them. A possible association between heterozygous COL4A3, COL4A4 and COL4A5 P/LP variants and KC has been described in small cohorts. The presence of KC in a multicenter cohort of individuals with heterozygous P/LP variants in the COL4A3 / COL4A4 genes is assessed in this study. We evaluated the presence of KC by ultrasound in 157 individuals with P/LP variants in COL4A3 (40.7%) or COL4A4 (53.5%) without kidney replacement therapy. The association between presence of KC and age, proteinuria, estimated glomerular filtration rate (eGFR) and causative gene was analyzed. Prevalence of KC was compared with historical case series in the general population. Half of the individuals with P/LP variants in COL4A3 / COL4A4 showed KC, which is a significantly higher percentage than in the general population. Only 3.8% (6/157) had cystic nephromegaly. Age and eGFR showed an association with the presence of KC (P <.001). No association was found between KC and proteinuria, sex or causative gene. Individuals with COL4A3 / COL4A4 P/LP variants are prone to develop KC more frequently than the general population, and their presence is related to age and to eGFR. Neither proteinuria, sex nor the causative gene influences the presence of KC in these individuals. OrderedDict([(u'fig', OrderedDict([(u'@position', u'float'), (u'@id', u'ga1'), (u'label', u'Graphical Abstract'), (u'graphic', OrderedDict([(u'@xlink:href', u'gfae031fig1g'), (u'@position', u'float')]))]))]).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inherited kidney disease and CAKUT are common causes of kidney failure requiring kidney replacement therapy, an ERA Registry study

  • Ortiz, Alberto|||0000-0002-9805-9523
  • Kramer, A.|||0000-0002-7560-2669
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Rodríguez Arévalo, Olga Lucia|||0009-0002-1442-3883
  • Gjerstad, A.C.
  • Santiuste, C.
  • Trujillo-Alemán, S.
  • Ferraro, Pietro Manuel|||0000-0002-1379-022X
  • Methven, S.
  • Santamaría, Rafael
  • Naumovic, R.
  • Resic, H.
  • Hommel, K.
  • Segelmark, M.|||0000-0002-1221-0772
  • Ambühl, P.M.
  • Sorensen, S. S.
  • Parmentier, C.
  • Vidal, E.
  • Bakkaloglu, S.A.|||0000-0001-6530-9672
  • Plumb, L.
  • Palsson, R.
  • Kerschbaum, J.|||0000-0002-6896-2279
  • ten Dam, M.A.G.J.
  • Stel, V.S.|||0000-0002-0007-1947
  • Jager, Kitty|||0000-0003-0444-8569
  • Torra Balcells, Roser|||0000-0001-8714-2332
Background. Inherited kidney diseases (IKDs) and congenital anomalies of the kidney and urinary tract (CAKUT) are causes of kidney failure requiring kidney replacement therapy (KRT) that major renal registries usually amalgamate into the primary renal disease(PRD) category 'miscellaneous' or in the glomerulonephritis or pyelonephritis categories. This makes IKDs invisible (except for polycystic kidney disease) and may negatively influence the use of genetic testing, which may identify a cause for IKDs and some CAKUT. Methods. We re-examined the aetiology of KRT by composing a separate IKD and CAKUT PRD group using data from the European Renal Association (ERA) Registry. Results. In 2019, IKD-CAKUT was the fourth most common cause of kidney failure among incident KRT patients, accounting for 8.9% of cases [IKD 7.4% (including 5.0% autosomal dominant polycystic kidney disease), CAKUT 1.5%], behind diabetes (23.0%), hypertension (14.4%) and glomerulonephritis (10.6%). IKD-CAKUT was the most common cause of kidney failure among patients <20 years of age (41.0% of cases), but their incidence rate was highest among those ages 45-74 years (22.5 per million age-related population). Among prevalent KRT patients, IKD-CAKUT (18.5%) and glomerulonephritis (18.7%) were the two most common causes of kidney failure overall, while IKD-CAKUT was the most common cause in women (21.6%) and in patients <45 years of age (29.1%). Conclusion. IKD and CAKUT are common causes of kidney failure among KRT patients. Distinct categorization of IKD and CAKUT better characterizes the epidemiology of the causes of chronic kidney disease (CKD) and highlights the importance of genetic testing in the diagnostic workup of CKD.